Your browser doesn't support javascript.
loading
Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome.
Takai, Mihoko; Yamauchi, Takahiro; Fujita, Kei; Lee, Shin; Ookura, Miyuki; Kishi, Shinji; Urasaki, Yoshimasa; Yoshida, Akira; Iwasaki, Hiromichi; Ueda, Takanori.
Afiliación
  • Takai M; Department of Hematology and Oncology, University of Fukui, Matsuoka, Eiheiji, Fukui 910-1193, Japan.
  • Yamauchi T; Department of Hematology and Oncology, University of Fukui, Matsuoka, Eiheiji, Fukui 910-1193, Japan.
  • Fujita K; Department of Hematology and Oncology, University of Fukui, Matsuoka, Eiheiji, Fukui 910-1193, Japan.
  • Lee S; Department of Hematology and Oncology, University of Fukui, Matsuoka, Eiheiji, Fukui 910-1193, Japan.
  • Ookura M; Department of Hematology and Oncology, University of Fukui, Matsuoka, Eiheiji, Fukui 910-1193, Japan.
  • Kishi S; Department of Hematology and Oncology, University of Fukui, Matsuoka, Eiheiji, Fukui 910-1193, Japan.
  • Urasaki Y; Department of Hematology and Oncology, University of Fukui, Matsuoka, Eiheiji, Fukui 910-1193, Japan.
  • Yoshida A; Department of Hematology and Oncology, University of Fukui, Matsuoka, Eiheiji, Fukui 910-1193, Japan.
  • Iwasaki H; Division of Infection Control, University of Fukui, Matsuoka, Eiheiji, Fukui 910-1193, Japan.
  • Ueda T; Department of Hematology and Oncology, University of Fukui, Matsuoka, Eiheiji, Fukui 910-1193, Japan.
Oncol Lett ; 8(4): 1523-1527, 2014 Oct.
Article en En | MEDLINE | ID: mdl-25202361
Tumor lysis syndrome (TLS) is a life-threatening oncological emergency, in which control of serum uric acid (S-UA) levels is important. S-UA-lowering efficacy of a new xanthine oxidase inhibitor, febuxostat, was retrospectively evaluated in seven patients with hematological malignancies who were at an intermediate risk of developing TLS. A 10-mg dose of febuxostat was initiated and chemotherapy was started within 24 h of administering the first dose of febuxostat. Febuxostat was continued until at least day 7 of chemotherapy treatment. The UA-lowering treatment was considered effective if febuxostat reduced S-UA levels to ≤7.5 mg/dl by day 5. The mean S-UA level at base line was 6.4±2.6 mg/dl and, on day 5, the mean S-UA level was 4.7±1.8 mg/dl. All the patients achieved S-UA levels ≤7.5 mg/dl. Serum creatinine levels decreased from 0.93±0.25 to 0.85±0.25 mg/dl. The estimated glomerular filtration rate values increased from 69.7±24.5 to 76.9±26.2 ml/min. No adverse reactions were noted during the study period and no patients experienced progressive TLS. Successful control of S-UA and improved renal function were obtained in response to febuxostat treatment in cancer patients at a risk of TLS.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Risk_factors_studies Idioma: En Revista: Oncol Lett Año: 2014 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Grecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Risk_factors_studies Idioma: En Revista: Oncol Lett Año: 2014 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Grecia